Boceprevir
- Generic Name
- Boceprevir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H45N5O5
- CAS Number
- 394730-60-0
- Unique Ingredient Identifier
- 89BT58KELH
- Background
Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of...
- Indication
Boceprevir, when used in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b is indicated for use in the treatment of chronic HCV genotype 1 infection in adults .
- Associated Conditions
- Chronic Hepatitis C Genotype 1
- Associated Therapies
- -
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Valme University Hospital
- Target Recruit Count
- 1128
- Registration Number
- NCT02333292
- Locations
- 🇪🇸
Valme University Hospital, Seville, Andalusia, Spain
Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT02204475
An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients
- Conditions
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT02118597
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
- Conditions
- Interventions
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Louis Stokes VA Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT02113631
- Locations
- 🇺🇸
Louis Stokes Cleveland VA medical center, Cleveland, Ohio, United States
Boceprevir in End Stage Renal Disease (ESRD)
- Conditions
- Interventions
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Columbia University
- Registration Number
- NCT02112630
Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)
- Conditions
- Interventions
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2018-07-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 257
- Registration Number
- NCT01945294
Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Markus Peck-Radosavljevic
- Target Recruit Count
- 6
- Registration Number
- NCT01925183
- Locations
- 🇦🇹
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Dutch Acute HCV in HIV Study (DAHHS)
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 65
- Registration Number
- NCT01912495
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Zuid Holland, Netherlands
🇳🇱OLVG, Amsterdam, Netherlands
🇳🇱Ziekenhuis Rijnstate, Arnhem, Netherlands
Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation
- Conditions
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 1
- Registration Number
- NCT01909401
- Locations
- 🇺🇸
Indiana University School of Medicine - IUHealth-University Hospital, Indianapolis, Indiana, United States
A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)
- First Posted Date
- 2013-01-17
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT01770223
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.